Biotechnology

INNOGEN-B

SinnoMed's First Domestic Long-Acting GLP-1 Generates Over 100 Million in Revenue in First Year but Net Loss Expands

Sinorx Biopharma Commercializes Isuglugrel

Sinono Pharmaceuticals Announces 2025 Annual Results with Expanded Losses

INNOGEN-B released FY2024 Q4 earnings on March 23 (BJT), actual revenue HKD 0, actual EPS HKD -0.1258

INNOGEN-B released FY2024 Q3 earnings on March 23 (BJT), actual revenue HKD 0, actual EPS HKD -0.1311

INNOGEN-B released FY2025 9 Months Earnings on March 23 Post-Market (BJT), actual revenue HKD 102.15 M, actual EPS HKD -0.5826

INNOGEN-B released FY2025 Q3 earnings on March 23, 2026 (BJT), actual revenue HKD 41.03 M, actual EPS HKD -0.2671

INNOGEN-B released FY2024 9-month earnings on March 23, 2026 (BJT), with actual revenue of HKD 0 and EPS of HKD -0.3249

INNOGEN-B released FY2025 Annual Earnings on March 23 After-Market (BJT), actual revenue HKD 143.73 M (forecast HKD 138.22 M), actual EPS HKD -0.8634 (forecast HKD -0.5336)

INNOGEN-B released FY2025 Q4 earnings on March 23 After-Market (BJT), actual revenue HKD 41.74 M, actual EPS HKD -0.2717

Silver No Medicine Issues Profit Warning: Expected Loss of 341 Million Yuan in 2025

INNOGEN-B to Release FY2025 Annual Earnings on March 23, 2026 After-Market (BJT), Forecast Revenue HKD 140.57 M, EPS HKD -0.5427

Innogen Pharmaceutical to be included in Hang Seng Composite Index, effective early March.

Innogen-B sees significant increase in Southbound capital holdings, leading in week-on-week growth.

Innogen-B expects to commence Phase I clinical trials for veterinary product in Q1.

Pfizer partners with Sciwind for GLP-1 drug, impacting Innogen's competitive landscape.

Innogen-B officially included in Hang Seng Composite Index; Stock Connect flows in focus.

Guangzhou Innogen Expected to Commence Veterinary Clinical Trials in Q1

Deutsche Bank Gives Innogen-B a Buy Rating with a Target Price of HK$34.60

Guangzhou Innogen Pharmaceutical (2591.HK) Cornerstone Investor Lock-up Period to Expire

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

06681

02591

09936

06166

00165

02587

02701

01979

09929

00697

BRAINAURORA-B(06681) rose 34.43%, with a trading turnover 1.8 Billion HKD, and a year-to-date fell 36.3%. INNOGEN-B(02591) rose 19.1%, with a trading turnover 724.2 Million HKD, and a year-to-date fell 53.2%. XIMEI RESOURCES(09936) rose 13.84%, with a trading turnover 38.2 Million HKD, and a year-to-date rose 170.8%.

Top Gainers&Losers

XIMEI RESOURCES

CHINA EB LTD

HEALTHYWAY INC

NSING TECH

TEN PAO GROUP

SEM HLDGS

SHOUCHENG

Top 10 HK Stock Gainers (5.19)

INNOGEN-B surged 21.10%; Peijia Medical-B had a transaction volume of HKD 856 million; Innovent Biologics fell 0.25%, with a transaction volume of HKD 562 million; CanSino Biologics fell 1.58%, with a transaction volume of HKD 553 million; BeiGene fell 0.29%, with a market value of HKD 269.1 billion

HK Stock Alerts

PEGBIO CO-B

INNOVENT BIO

AKESO

BEONE MEDICINES

Hong Kong stock movement: INNOGEN-B surged 21.10%, with clear capital flow; what is stirring the market sentiment?

INNOGEN-B rose 18.69%; Peijia Medical-B rose 0.91%, with a transaction amount reaching HKD 839 million; Innovent Biologics fell 0.56%, with a transaction amount reaching HKD 522 million; CanSino Biologics fell 1.49%, with a transaction amount reaching HKD 520 million; BeiGene fell 0.91%, with a market value of HKD 267.4 billion

Hong Kong Stock Movement: INNOGEN-B rises 18.69%, with clear capital flow, market sentiment triggers volatility attention

INNOGEN-B surged 36.63%; Peijia Medical-B rose 5.70%, with a transaction volume of HKD 411 million; Innovent Biologics increased by 0.62%, with a transaction volume of HKD 292 million; CanSino Biologics fell by 0.62%, with a transaction volume of HKD 240 million; BeiGene rose by 1.03%, with a market capitalization of HKD 272.7 billion

Hong Kong Stock Movement: INNOGEN-B surged 36.63%, with clear capital flow; what risks are hidden behind the rising market sentiment?

INNOGEN-B rose 19.44%; Peijia Medical-B rose 11.77%, with a transaction volume of HKD 380 million; Innovent Biologics rose 0.12%, with a transaction volume of HKD 277 million; CanSino Biologics fell 0.62%, with a transaction volume of HKD 230 million; BeiGene rose 0.63%, with a market value of HKD 271.6 billion

Hong Kong stock movement: INNOGEN-B rose by 19.44%, with clear capital flow, market sentiment triggered volatility attention

01236

00650

00326

09858

00470

01729

01117

09993

LDROBOT(01236) fell 14%, with a trading turnover 181.1 Million HKD, and a year-to-date rose 95.8%. PRODUCTIVE TECH(00650) fell 12.12%, with a trading turnover 38.3 Million HKD, and a year-to-date rose 208.5%. CHINA STAR ENT(00326) fell 11.41%, with a trading turnover 239.3 Million HKD, and a year-to-date rose 179.7%.

LDROBOT

PRODUCTIVE TECH

CHINA STAR ENT

YOURAN DAIRY

WUXI LEAD

TIME INTERCON

CH MODERN D

RADIANCE HLDGS

Top 10 HK Stock Losers (5.12)

02659

02635

00819

01858

06869

02442

02650

01907

00631

BAO PHARMA-B(02659) fell 65.55%, with a trading turnover 785.1 Million HKD, and a year-to-date fell 66.7%. NUOBIKAN(02635) fell 31.2%, with a trading turnover 281.8 Million HKD, and a year-to-date fell 47.2%. TIANNENG POWER(00819) fell 27.25%, with a trading turnover 720.0 Million HKD, and a year-to-date fell 19%.

BAO PHARMA-B

NUOBIKAN

TIANNENG POWER

CHUNLI MEDICAL

YOFC

EASY SMART GP

ZHIDA TECH

CHINA RISUN GP

SANY INT'L

Top 10 HK Stock Losers (4.30)

02565

06656

02556

02465

02160

09678

NUOBIKAN(02635) fell 33.69%, with a trading turnover 322.5 Million HKD, and a year-to-date rose 21.4%. PEGBIO CO-B(02565) fell 13.79%, with a trading turnover 24.9 Million HKD, and a year-to-date fell 47.8%. SIGENERGY(06656) fell 9.37%, with a trading turnover 587.7 Million HKD, and a year-to-date rose 67%.

INNOGEN-B(02591.HK)